4-n-butylresorcinol dissolving microneedle patch for skin depigmentation: a randomized, double-blind, placebo-controlled trial

Journal of Cosmetic Dermatology
Suyong KimHyungil Jung

Abstract

For effective skin depigmentation, the skin depigmentation agent must be delivered to melanocytes, where melanin is synthesized. Although dissolving microneedle (DMN) is one of the best transdermal drug delivery systems to deliver the active compound, no clinical trial has been conducted in terms of safety and efficacy. To assess the clinical efficacy and safety of a DMN patch that contained 4-n-butylresorcinol, a skin depigmentation agent. In the safety assessment, 31 subjects were selected for primary skin irritation test using Frosch & Kligman's method and 50 women for the cumulative irritation test and sensitization potential test using a modification of the Shelanski-Shelanski method. In the efficacy assessment, the 4-n-butylresorcinol DMN patch was compared with a control (DMN without 4-n-butylresorcinol) in our double-blind, placebo-controlled study with 45 subjects by measuring two parameters, the melanin index and individual typology angle value, during 8 weeks of administration. The 4-n-butylresorcinol DMN patch was shown to be safe based on the results of the safety assessment and was more than two times effective than the control patch. The 4-n-butylresorcinol DMN patch was effective and safe for skin depigmentation...Continue Reading

References

Jul 1, 1979·Journal of the American Academy of Dermatology·P J Frosch, A M Kligman
May 30, 1998·Methods and Findings in Experimental and Clinical Pharmacology·K TasakaM Yamato
Sep 21, 2000·Pharmaceutical Science & Technology Today·A NaikR H Guy
Apr 29, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·M B Brown, S A Jones
May 4, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jung-Hwan ParkMark R Prausnitz
Jan 24, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Gertrude-E Costin, Vincent J Hearing
Apr 11, 2007·Archives of Internal Medicine·James T Cross
Feb 12, 2008·Biomaterials·Jeong W LeeMark R Prausnitz
Apr 26, 2008·Photochemistry and Photobiology·Michaela Brenner, Vincent J Hearing
Jul 8, 2009·International Journal of Molecular Sciences·Te-Sheng Chang
Oct 30, 2009·International Journal of Molecular Sciences·Jody P EbanksRaymond E Boissy
Jul 20, 2010·Nature Medicine·Sean P SullivanMark R Prausnitz
May 12, 2012·Advanced Drug Delivery Reviews·Yeu-Chun KimMark R Prausnitz
Oct 13, 2012·International Journal of Cosmetic Science·K H Son, M Y Heo
Dec 12, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·L KolbeF Stäb
Jun 8, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jung Dong KimHyungil Jung

❮ Previous
Next ❯

Citations

Apr 4, 2019·Dermatologic Therapy·Ye Jin LeeChong Hyun Won
Apr 6, 2018·Skin Pharmacology and Physiology·Chisong LeeHyungil Jung
Apr 13, 2019·Dermatologic Therapy·Begüm Ünlü, Ümit Türsen
Nov 25, 2020·Pharmaceutics·Seung-Yeon JeongSong-Yi Kim
Sep 27, 2020·Archives of Dermatological Research·Clarissa L M da Silva BergmannCaroline Dani
May 30, 2021·International Journal of Pharmaceutics·Lijing ZhangPeng Zhang
Jul 21, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Mengzhen XingYunhua Gao
Nov 27, 2021·Journal of Cosmetic Dermatology·Yonghao MaGang Leng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.